Invitrogen's innovative solutions in the drug discovery continuum and Glaxo completes $1.4B purchase of flu vaccine maker.

0 Comments | M2 Presswire, December, 2005

M2 PRESSWIRE-9 December 2005-US Financial Network: Invitrogen's innovative solutions in the drug discovery continuum and Glaxo completes $1.4B purchase of flu vaccine maker(C)1994-2005 M2 COMMUNICATIONS LTD RDATE:09122005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU) Frost & Sullivan selected Invitrogen Corporation (Nasdaq: IVGN) as the recipient of the 2005 Drug Discovery Technologies Company of the Year Award for showing great resourcefulness in penetrating the new drug discovery technology markets with exceptional marketing strategy and resulting in revenue growth.

Each year, Frost & Sullivan presents this Award to a company that has exhibited excellence in all operations - business development, competitive...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)